240 related articles for article (PubMed ID: 26458285)
1. Enhanced antitumor effect of cisplatin in human oral squamous cell carcinoma cells by tumor suppressor GRIM‑19.
Li M; Li Z; Li J; Jin L; Jin C; Han C; Ji X; Sun F
Mol Med Rep; 2015 Dec; 12(6):8185-92. PubMed ID: 26458285
[TBL] [Abstract][Full Text] [Related]
2. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
3. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
4. Galectin‑3 blockade suppresses the growth of cetuximab‑resistant human oral squamous cell carcinoma.
Yin P; Cui S; Liao X; Yao X
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328195
[TBL] [Abstract][Full Text] [Related]
5. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
Wang X; Li H; Shi J
Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
[TBL] [Abstract][Full Text] [Related]
6. Additive effects of eukaryotic co‑expression plasmid carrying GRIM‑19 and LKB1 genes on breast cancer in vitro and in vivo.
Zhang W; Shao Y; Du Y; Geng W; Jiang T; Liu H; Zhang D
Mol Med Rep; 2015 Nov; 12(5):7665-72. PubMed ID: 26458553
[TBL] [Abstract][Full Text] [Related]
7. Taurolidine promotes cell apoptosis by enhancing GRIM‑19 expression in liver cancer.
Li F; Qi J; Qin C; Fu Z; Ren W
Oncol Rep; 2018 Dec; 40(6):3743-3751. PubMed ID: 30272302
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of GRIM-19 suppresses the growth of oral squamous cell carcinoma in vitro and in vivo.
Li M; Li Z; Liang C; Han C; Huang W; Sun F
Oncol Rep; 2014 Nov; 32(5):2183-90. PubMed ID: 25174621
[TBL] [Abstract][Full Text] [Related]
9. MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1.
Chen L; Zhu Q; Lu L; Liu Y
Bioengineered; 2020 Dec; 11(1):91-102. PubMed ID: 31906769
[TBL] [Abstract][Full Text] [Related]
10. Effects of CRM197, a specific inhibitor of HB-EGF, in oral cancer.
Dateoka S; Ohnishi Y; Kakudo K
Med Mol Morphol; 2012 Jun; 45(2):91-7. PubMed ID: 22718294
[TBL] [Abstract][Full Text] [Related]
11. 1'-Acetoxychavicol acetate inhibits growth of human oral carcinoma xenograft in mice and potentiates cisplatin effect via proinflammatory microenvironment alterations.
In LL; Arshad NM; Ibrahim H; Azmi MN; Awang K; Nagoor NH
BMC Complement Altern Med; 2012 Oct; 12():179. PubMed ID: 23043547
[TBL] [Abstract][Full Text] [Related]
12. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of co-expression plasmid‑based ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo.
Liu S; Zhang W; Liu K; Wang Y; Ji B; Liu Y
Oncol Rep; 2014 Dec; 32(6):2501-10. PubMed ID: 25242535
[TBL] [Abstract][Full Text] [Related]
14. MiR-222 targeted PUMA to improve sensitization of UM1 cells to cisplatin.
Jiang F; Zhao W; Zhou L; Liu Z; Li W; Yu D
Int J Mol Sci; 2014 Dec; 15(12):22128-41. PubMed ID: 25474084
[TBL] [Abstract][Full Text] [Related]
15. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
[TBL] [Abstract][Full Text] [Related]
16. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma.
Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R
Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760
[TBL] [Abstract][Full Text] [Related]
18. FOXO3a reactivation mediates the synergistic cytotoxic effects of rapamycin and cisplatin in oral squamous cell carcinoma cells.
Fang L; Wang H; Zhou L; Yu D
Toxicol Appl Pharmacol; 2011 Feb; 251(1):8-15. PubMed ID: 21092744
[TBL] [Abstract][Full Text] [Related]
19. Nonviral Delivery of
Xu Y; Wang X; Guo B; Wang D; Kalvakolanu DV; Chen X; Tang J; Zhang L; Yang Q
Hum Gene Ther; 2019 Nov; 30(11):1419-1430. PubMed ID: 31382833
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect of cisplatin in human oral squamous cell carcinoma was enhanced by andrographolide via upregulation of phospho-p53 in vitro and in vivo.
Chen S; Hu H; Miao S; Zheng J; Xie Z; Zhao H
Tumour Biol; 2017 May; 39(5):1010428317705330. PubMed ID: 28513299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
